Imagine you're a pharma company trying to find drugs for Alzheimer's or Parkinson's, but your lab tests use flat layers of cells that don't behave like real brain tissue. This project built 3D mini-brain-tissue kits — human nerve cells grown on printed scaffolds, frozen and shipped in standard lab plates, ready to use straight out of the box. It's like going from testing paint on a flat wall to testing it on the actual building. Four European SMEs each brought a piece of the puzzle: one makes the brain cells from stem cells, one prints the 3D scaffolds, one adds the biological glue, and one freezes and packages the final product.
Neurodegenerative diseases like Alzheimer's and Parkinson's remain without effective treatments, creating an unsustainable global healthcare burden. Drug discovery for these conditions is particularly difficult because standard flat cell cultures fail to replicate the complex 3D environment of real brain tissue, leading to poor predictive accuracy in early screening and high failure rates in clinical trials.
The project built ready-to-use 3D neural cell screening kits in standard multiwell plate formats. Specifically, it delivered two product types — a single-cell 3D neural model and a dual-cell 3D neural model — complete with production SOPs and product information sheets for both.
If you are a pharma company screening drug candidates for Alzheimer's or Parkinson's — this project developed 3D neural cell kits delivered in multiwell plates ready for industrial screening. Each contributing technology started at TRL 6, and the consortium of 4 SME partners assembled them into first-to-market screening formats that offer better predictive value than flat cell cultures.
If you are a CRO that runs drug screening assays for clients and want to differentiate with more predictive human neural models — this project produced iPSC-derived neural cells cryopreserved in single-cell and dual-cell 3D formats. The kits arrive ready to use in standard multiwell plates, cutting your setup time and improving the reliability of results you deliver to pharma clients.
If you are a biotech company looking to expand your product catalog with advanced neural screening tools — this project combined iPSC differentiation, 3D bioprinting, peptide dendron chemistry, and cryopreservation into a complete product line. The consortium produced standard operating procedures and product information sheets for both single-cell and dual-cell 3D models, giving you a replicable manufacturing blueprint.
The project data does not include pricing information. However, the product is designed for industrial-scale screening in standard multiwell plates, suggesting pricing competitive with existing cell-based assay kits. Contact the coordinator AvantiCell Science Ltd for commercial pricing.
Yes, the project specifically targeted industrial screening applications. Deliverables include production SOPs (Standard Operating Procedures) for both single-cell and dual-cell 3D models, and the kits use standard multiwell plate formats already used across pharma. Each contributing technology was at TRL 6 at project start.
The consortium consists of 4 commercial SMEs, each contributing proprietary technology: Phenocell (iPSC differentiation), Cellink (bioprinting/bio-inks), Tissue Click (peptide dendrons), and AvantiCell Science (cryopreservation/validation). Licensing discussions would need to go through AvantiCell Science Ltd as coordinator.
The project describes its output as 'first-to-market formats beyond the current state of the art.' The key differentiator is combining human iPSC-derived neural cells with 3D printed scaffolds and cryopreservation — delivering a ready-to-use 3D human brain tissue model rather than the flat 2D cell layers commonly used in screening.
The deliverables include validated cell products with product information sheets for both single-cell and dual-cell models. However, the project data does not mention specific regulatory approval (FDA, EMA). Based on available project data, validation was focused on analytical performance rather than regulatory clearance.
The project focuses on neurodegenerative diseases broadly. The iPSC-derived cells are produced using protocols shown to generate glial and neuronal cell lineages and to reinstate donor disease phenotypes, meaning the cells can model specific patient diseases. The exact disease targets are not specified beyond neurodegeneration.
This is a rare 100% commercial consortium — all 4 partners are SMEs with no universities or research institutes. Each partner brings a distinct, essential capability: Phenocell (France) produces iPSC-derived neural cells, Cellink (Sweden) provides bioprinting hardware and bio-inks, Tissue Click (UK) contributes proprietary peptide dendron chemistry, and coordinator AvantiCell Science (UK) handles validation, cryopreservation, and product packaging. The absence of academic partners and the Fast Track to Innovation funding scheme signal that this project was explicitly about commercializing existing technologies, not conducting basic research. For a potential buyer or licensing partner, the clear IP ownership across 4 distinct technology contributions simplifies negotiation — you know exactly who owns what.
AvantiCell Science Ltd is a UK-based SME specializing in cell-based assay products. Search for their team on LinkedIn or visit avanticell.com for contact details.
Want an introduction to the CENSUS team or a detailed technology brief? SciTransfer can connect you with the right person and prepare a tailored assessment of how this fits your screening pipeline.
